Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy

References

• Ostrom Q, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-Oncology. 2018;20:iv1–iv86. doi:10.1093/neuonc/noy13130445539
   PubMed Web of Science ®Google Scholar
• Tan A, Ashley D, López G, Malinzak M, Friedman H, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70:299–312. doi:10.3322/caac.2161332478924
   PubMed Web of Science ®Google Scholar
• Taphoorn M, Sizoo E, Bottomley A. Review on quality of life issues in patients with primary brain tumors. Oncologist. 2010;15(6):618–626. doi:10.1634/theoncologist.2009-029120507891
   PubMed Web of Science ®Google Scholar
• Louis D, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi M, Mason W, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi:10.1016/S1470-2045(09)70025-719269895
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason W, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• Koshy M, Villano J, Dolecek T, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107(1):207–212. doi:10.1007/s11060-011-0738-721984115
   PubMed Web of Science ®Google Scholar
• Ostrom Q, Cote D, Ascha M, Kruchko C, Barnholtz-Sloan J. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA oncol. 2018;4(9):1254–1262. doi:10.1001/jamaoncol.2018.178929931168
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney D, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–198. doi:10.3171/jns.2001.95.2.0190
   PubMed Web of Science ®Google Scholar
• Lamborn K, Chang S, Prados M. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncology. 2004;6(3):227–235. doi:10.1215/S115285170300062015279715
   PubMed Web of Science ®Google Scholar
• Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Research Clin Oncol. 2003;129(8):477–484. doi:10.1007/s00432-003-0471-512884028
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• McMillan D. The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.00322995477
   PubMed Web of Science ®Google Scholar
• Bao Y, Yang M, Jin C, et al. Preoperative hematologic inflammatory markers as prognostic factors in patients with glioma. World Neurosurg. 2018;119:e710–e716. doi:10.1016/j.wneu.2018.07.25230092479
   PubMed Web of Science ®Google Scholar
• Wang P, Meng Z, Song H, et al. Preoperative changes in hematological markers and predictors of glioma grade and survival. Front Pharmacol. 2018;9:886. doi:10.3389/fphar.2018.0088630154718
   PubMed Web of Science ®Google Scholar
• Mandoj C, Tomao L, Conti L.Coagulation in brain tumors: biological basis and clinical implications. Front Neurol. 2019;10(181). doi:10.3389/fneur.2019.00181
   Web of Science ®Google Scholar
• SE N, Guarnaccia L, Locatelli M, et al. Significance and prognostic value of the coagulation profile in patients with glioblastoma: implications for personalized therapy. World Neurosurg. 2019;121:e621–e629. doi:10.1016/j.wneu.2018.09.17730292037
   PubMed Web of Science ®Google Scholar
• Hagan K, Bhavsar S, Arunkumar R, et al. Association between perioperative hyperglycemia and survival in patients with glioblastoma. J Neurosurg Anesthesiol. 2017;29(1):21–29. doi:10.1097/ANA.000000000000033927438798
   PubMed Web of Science ®Google Scholar
• Xu W, Li F, Xu Z, et al. Preoperative albumin-to-globulin ratio and prognostic nutrition index predict prognosis for glioblastoma. Onco Targets Ther. 2017;10:725–733. doi:10.2147/OTT.S12744128223828
   PubMed Web of Science ®Google Scholar
• Zhou X, Dong H, Yang Y, et al. Significance of the prognostic nutritional index in patients with glioblastoma: A retrospective study. Clin Neurol Neurosurg. 2016;151:86–91. doi:10.1016/j.clineuro.2016.10.01427816892
   PubMed Web of Science ®Google Scholar
• Kim J, Han J, Jang Y. High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma. Int J Oncol. 2015;47(3):1009–1016. doi:10.3892/ijo.2015.310126202438
   PubMed Web of Science ®Google Scholar
• RF L, Li M, Yang Y, Mao Q, Liu Y-H. Significance of pretreatment red blood cell distribution width in patients with newly diagnosed glioblastoma. Med Sci Monitor. 2017;23:3217–3223. doi:10.12659/MSM.905204
   PubMed Web of Science ®Google Scholar
• Bouchart C, Trépant A, Hein M, Van Gestel D, Demetter P. Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2. Cancer Med. 2020;9(3):1069–1078. doi:10.1002/cam4.259231568682
   PubMed Web of Science ®Google Scholar
• Wasserman J, Nicholas G, Yaworski R, et al. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. PLoS One. 2015;10(4):e0123890. doi:10.1371/journal.pone.012389025849605
   PubMed Web of Science ®Google Scholar
• Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer In: MacLeod C, editor. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191–205.
   Google Scholar
• Pirracchio R, Resche-Rigon M, Bresson D, et al. One-year outcome after neurosurgery for intracranial tumor in elderly patients. J Neurosurg Anesthesiol. 2010;22(4):342–346. doi:10.1097/ANA.0b013e3181e6daa220622683
   PubMed Web of Science ®Google Scholar
• Villani V, Pace A, Vidiri A, et al. Phase II study of weekly carboplatin in pretreated adult malignant gliomas. J Neurooncol. 2019;144(1):211–216.31273578
   PubMed Web of Science ®Google Scholar
• Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655. doi:10.1097/00000421-198212000-000147165009
   PubMed Web of Science ®Google Scholar
• Lynes J, Nwankwo A, Sur H, et al. Biomarkers for immunotherapy for treatment of glioblastoma. J Immunotherapy Cancer. 2020;8:1. doi:10.1136/jitc-2019-000348
   Web of Science ®Google Scholar
• Le Rhun E, Preusser M, Roth P, et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896. doi:10.1016/j.ctrv.2019.10189631541850
   PubMed Web of Science ®Google Scholar
• Charrier M, Mezquita L, Lueza B, et al. Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. Eur J Cancer. 2019;108:88–96. doi:10.1016/j.ejca.2018.12.01730648633
   PubMed Web of Science ®Google Scholar
• Xu Z, Xu W, Cheng H, et al. The prognostic role of the platelet-lymphocytes ratio in gastric cancer: a meta-analysis. PLoS One. 2016;11(9):e0163719. doi:10.1371/journal.pone.016371927684077
   PubMed Web of Science ®Google Scholar
• Li L, Bai Z, Zhang L, et al. Meta-analysis of hematological biomarkers as reliable indicators of soft tissue sarcoma prognosis. Front Oncol. 2020;10:30. doi:10.3389/fonc.2020.0003032082998
   PubMed Web of Science ®Google Scholar
• Adeberg S, Bostel T, König L, Welzel T, Debus J, Combs S. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? Radiation Oncol. 2014;9:95. doi:10.1186/1748-717X-9-95
   PubMed Web of Science ®Google Scholar
• Dietterle J, Wende T, Wilhelmy F, et al. The prognostic value of peri-operative neurological performance in glioblastoma patients. Acta Neurochir. 2020;162(2):417–425. doi:10.1007/s00701-019-04136-431736002
   PubMed Web of Science ®Google Scholar
• Wang D, Kang K, Lin Q, Hai J. Prognostic significance of preoperative systemic cellular inflammatory markers in gliomas: a systematic review and meta-analysis. Clin Transl Sci. 2020;13(1):179–188. doi:10.1111/cts.1270031550075
   PubMed Web of Science ®Google Scholar
• Mostofa A, Punganuru S, Madala H, Al-Obaide M, Srivenugopal K. The process and regulatory components of inflammation in brain oncogenesis. Biomolecules. 2017;7(4):2. doi:10.3390/biom7020034
   PubMed Web of Science ®Google Scholar
• Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer. 2015;15:617. doi:10.1186/s12885-015-1629-726341881
   PubMed Web of Science ®Google Scholar
• Ding J, Karp J, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomarkers. 2017;19(4):353–363. doi:10.3233/CBM-16033628582845
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncologica. 2015;54(7):961–970. doi:10.3109/0284186X.2015.104302625984930
   PubMed Web of Science ®Google Scholar
• Zhang J, Yao Y, Li B, Yang Q, Zhang P, Wang H. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep. 2015;5:9800. doi:10.1038/srep0980025902419
   PubMed Web of Science ®Google Scholar